<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2012-05-01 15:28:24HIV/AIDS ViiV Healthcare Fixed dose combination GlaxoSmithKline Pfizer Zidovudine Lamivudine Intel Viiv Abacavir/lamivudine Medicine Health Pharmacology |
Add to Reading List |
PRESS RELEASE ANNOUNCEMENT | Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegravDocID: 1ai1w - View Document |
| PDF DocumentDocID: 19Erl - View Document |
| Microsoft Word - 20130218_FDA Priority Review Designation for DTG_E_FinalDocID: 19CeI - View Document |
| Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & CDocID: 19rEm - View Document |
| PDF DocumentDocID: 19p8F - View Document |